These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature. Zhang Y; Wright C; Flores A J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601 [TBL] [Abstract][Full Text] [Related]
8. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO. Enzinger C Mult Scler; 2017 May; 23(6):767-770. PubMed ID: 28287038 [No Abstract] [Full Text] [Related]
9. Evolution of MRI appearances due to progressive multifocal leucoencephalopathy following natalizumab treatment for multiple sclerosis. Campbell S; Kanodia AK; O'Riordan J BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25878241 [No Abstract] [Full Text] [Related]
10. [Natalizumab can induce progressive multifocal leucoencephalopathy]. Theódórsdóttir A; Blaabjerg M; Falah M Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706 [TBL] [Abstract][Full Text] [Related]
11. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES. Yap SM; McGuigan C Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039 [No Abstract] [Full Text] [Related]
12. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113 [TBL] [Abstract][Full Text] [Related]
14. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay. O'Connor PW Can J Neurol Sci; 2012 Sep; 39(5):670-5. PubMed ID: 22931715 [No Abstract] [Full Text] [Related]
15. Risk factors for rare diseases can be risky to define: PML and natalizumab. Major EO; Douek DC Neurology; 2013 Sep; 81(10):858-9. PubMed ID: 23925759 [No Abstract] [Full Text] [Related]
16. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy. Budhram A; Pelikan JB; Kremenchutzky M; Sharma M J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156 [No Abstract] [Full Text] [Related]
18. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks. Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520 [No Abstract] [Full Text] [Related]
19. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No. Labauge P Rev Neurol (Paris); 2017 Dec; 173(10):614-615. PubMed ID: 29102328 [No Abstract] [Full Text] [Related]
20. Considerations for characterizing the risk of PML in natalizumab-treated patients. Koendgen H; Ho PR; Chang I Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357 [No Abstract] [Full Text] [Related] [Next] [New Search]